基于纳米抗体的SPECT放射性示踪剂99mTc-AFN的临床前评估:用于无创监测心肌梗死后成纤维细胞活化的临床潜力
本研究制备了高亲和力靶向成纤维细胞活化蛋白的99mTc标记纳米抗体99mTc-AFN,在小鼠缺血再灌注心肌梗死模型中进行动态SPECT/CT成像,并与99mTc-HFAPi对比,同时在猪心肌梗死模型中进行验证。结果显示梗死区摄取在注射后1小时最清晰,第3天可见、第7天达最大,梗死区与非梗死区摄取比值99mTc-AFN为2.23±0.82、99mTc-HFAPi为1.34±0.21(P=.05),作者认为99mTc-AFN有潜力用于无创监测心肌梗死后成纤维细胞活化。
要点
- 99mTc-AFN在注射后1小时梗死区显影最清晰,第3天可见摄取、第7天达最大。
- 梗死区/非梗死区摄取比值99mTc-AFN 2.23±0.82 vs 99mTc-HFAPi 1.34±0.21(P=.05)。
- 免疫组化证实第7天心肌纤维化和FAP表达达最大,与影像摄取时相一致。
核心结论
- 本研究显示99mTc-AFN有潜力用于无创监测心肌梗死后成纤维细胞活化,可能成为临床成像的新选择。
研究设计与样本
- 临床前研究:采用位点特异性标记制备99mTc-AFN,在8周龄雄性C57/BL6小鼠缺血再灌注损伤第7天(n=4)行注射后0.5至4小时动态SPECT/CT成像。
关键影像表现/征象
- 99mTc-AFN在梗死区的聚集在注射后1小时最清晰可见。
- SPECT/CT图像上梗死心肌的99mTc-AFN摄取自第3天可见,最大摄取出现在第7天。
- 免疫组化检查证实最大心肌纤维化和FAP表达见于第7天。
- 猪心肌梗死模型第7天亦清晰显示梗死心肌的99mTc-AFN摄取。
诊断标准与关键数值
- 注射后1小时,梗死区与非梗死区摄取比值(均值±标准差):99mTc-AFN 2.23±0.82 vs 99mTc-HFAPi 1.34±0.21(P=.05)。
- 注射后1小时,梗死区与血液摄取比值(均值±标准差):99mTc-AFN 1.08±0.49 vs 99mTc-HFAPi 0.89±0.42(P=.34)。
临床应用与阅片要点
- 缺血再灌注小鼠模型于术后第3、7、14、28天注射后1小时行99mTc-AFN SPECT/CT成像以观察摄取时相变化。
- 第7天进行离体SPECT/CT成像、阻断成像和生物分布研究,并与99mTc-HFAPi对比。
- 猪心肌梗死模型于第7天进行99mTc-AFN临床前评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To explore the feasibility of a new technetium 99m-labeled nanobody (99mTc-antifibroblast activation protein nanobody [AFN]) with high affinity to fibroblast activation protein for noninvasive monitoring of fibroblast activation after myocardial infarction. Materials and Methods 99mTc-AFN was prepared by site-specific labeling. Dynamic SPECT/CT imaging from 0.5 to 4 hours after injection of 99mTc-AFN was performed in male C57/BL6 mice at 8 weeks of age with the ischemia-reperfusion (IR) injury on day 7 (n = 4). Furthermore, IR mice underwent 99mTc-AFN SPECT/CT imaging on postoperative days 3, 7, 14, and 28 at 1 hour following injection. Ex vivo SPECT/CT imaging, blocking imaging, and biodistribution studies were performed on day 7 and compared with a 99mTc-labeled fibroblast activation protein inhibitor (FAPI)-04-derived radiotracer (99mTc-HFAPi). Preclinical evaluation of 99mTc-AFN in a swine model of myocardial infarction was performed on day 7. Biodistributions and quantitative results were compared between groups using analysis of variance and t tests. Results The accumulation of 99mTc-AFN at the infarcted region was most clearly visible at 1 hour following injection. 99mTc-AFN uptake on SPECT/CT images in the infarcted myocardium was visible from day 3, and maximum uptake occurred on day 7. At 1 hour after injection, the 99mTc-AFN and 99mTc-HFAPi uptake ratios (means ± SDs) were 2.23 ± 0.82 versus 1.34 ± 0.21 (P = .05), respectively, for infarcted to noninfarcted regions and 1.08 ± 0.49 versus 0.89 ± 0.42 (P = .34) for infarcted region to blood, respectively. Immunohistochemical examinations confirmed that maximum myocardium fibrosis and FAP expression was observed on day 7. 99mTc-AFN uptake in the infarcted myocardium was also clearly visualized with the swine model of myocardial infarction. Conclusion This study demonstrated the potential of 99mTc-AFN for noninvasive monitoring of fibroblast activation after myocardial infarction, which may be a new option for clinical imaging. Keywords: Fibroblast Activation Protein, Nanobody, 99mTc-AFN, 99mTc-HFAPi, Myocardial Infarction Supplemental material is available for this article. © RSNA, 2025.
引用
- Ai Z, Li C, Yang Y, et al. Preclinical Evaluation of a Nanobody-based SPECT Radiotracer 99mTc-AFN with Clinical Potential for Noninvasive Monitoring of Fibroblast Activation after Myocardial Infarction. Radiol Cardiothorac Imaging. 2025. PMID: 40402089. doi:10.1148/ryct.240204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。